Quick Answer
Estrella Immunopharma, Inc. reported Total Assets of $3.18 million for fiscal year 2025.
Estrella Immunopharma, Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $3.18M | +1.2% |
| 2024 | $3.14M | -29.5% |
| 2024 | $4.45M | +47.1% |
| 2023 | $3.03M | -68.9% |
| 2022 | $9.72M | -78.8% |
| 2021 | $45.80M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $3.52M | -5.7% | +18.2% |
| June 30, 2025 | $2.98M | -33.1% | +21.9% |
| March 31, 2025 | $2.44M | -71.7% | -22.2% |
| December 31, 2024 | $3.14M | -66.8% | -15.9% |
| September 30, 2024 | $3.74M | -86.3% | -16.1% |
| June 30, 2024 | $4.45M | +47.1% | -48.4% |
| March 31, 2024 | $8.63M | -11.7% | -8.6% |
| December 31, 2023 | $9.45M | -2.8% | -65.5% |
- Estrella Immunopharma, Inc. showed an increase of +1.2% in Total Assets compared to the prior fiscal year.
- Over the 2021–2025 period, Estrella Immunopharma, Inc.’s total assets has declined by 93.1% (from $45.80 million to $3.18 million).
- The most recent figure is from Estrella Immunopharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: